WC
Therapeutic Areas
Sarepta Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Duchenne Muscular Dystrophy (DMD) | Marketed / Phase 3 |
| SRP-5051 (vesleteplirsen) | Duchenne Muscular Dystrophy (DMD) | Phase 2 |
| SRP-9003 | Limb-Girdle Muscular Dystrophy Type 2E/R4 | Phase 3 |
| SRP-6004 | Myotonic Dystrophy Type 1 (DM1) | Phase 1/2 |
| SRP-6005 | Facioscapulohumeral Muscular Dystrophy (FSHD1) | Phase 1/2 |
| EXONDYS 51 (eteplirsen) | Duchenne Muscular Dystrophy (DMD) | Marketed |
| VYONDYS 53 (golodirsen) | Duchenne Muscular Dystrophy (DMD) | Marketed |
| AMONDYS 45 (casimersen) | Duchenne Muscular Dystrophy (DMD) | Marketed |
Leadership Team at Sarepta Therapeutics
DS
Douglas S. Ingram
President and Chief Executive Officer
SM
Sandy Mahatme
EVP, Chief Financial Officer & Chief Business Officer
DL
Dr. Louise Rodino-Klapac
EVP, Head of R&D and Chief Scientific Officer
DG
Dr. Gilmore O'Neill
EVP, Head of R&D and Chief Medical Officer
MC
Michael Chambers
SVP, Chief Commercial Officer
DA
Dr. Arthur A. Levin
EVP, Head of Research and Development
DM
Dr. M. Kathleen Behrens
Chair of the Board of Directors